Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best–Worst Scaling

Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best–Worst Scaling

Martine C Maculaitis,1 Xianchen Liu,2 Oliver Will,3 Madelyn Hanson,4 Lynn McRoy,2 Alexandra Berk,1 Melissa Crastnopol3 1Kantar, Health Division, New York, NY, USA; 2Pfizer Oncology, Pfizer Inc, New York, NY, USA; 3Kantar, Health Division, Horsham, PA, USA; 4Kantar, Health Division, St. Louis, MO, US...

Full description

Bibliographic Details
Main Authors: Maculaitis MC, Liu X, Will O, Hanson M, McRoy L, Berk A, Crastnopol M
Format: Article
Language:English
Published: Dove Medical Press 2020-11-01
Series:Patient Preference and Adherence
Subjects:
adverse events
metastatic hr positive/her2 negative breast cancer
selective cyclin-dependent 4/6 kinase inhibitors
stakeholder preferences
treatment administration
treatment choice
Online Access:https://www.dovepress.com/oncologist-and-patient-preferences-for-attributes-of-cdk46-inhibitor-r-peer-reviewed-article-PPA

Internet

https://www.dovepress.com/oncologist-and-patient-preferences-for-attributes-of-cdk46-inhibitor-r-peer-reviewed-article-PPA

Similar Items